Missouri- and New Jersey-based drugmaker Nostrum Laboratories and its founder and CEO, Dr. Nirmal Mulye, have agreed to pay a minimum of $3,825,000 – and up to $50 million if certain financial contingencies are met – to resolve allegations that they violated the False Claims Act by knowingly underpaying Medicaid rebates due for Nostrum’s drug Nitrofurantoin Oral Suspension (Nitro OS).